Zymeworks Inc (Zymeworks) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company's lead product candidates are Zanidatamab for the treatment of biliary tract cancers, breast cancer, gastroesophageal adenocarcinomas and colorectal cancer, Zanidatamab Zovodotin for HER2-expressing cancers. Its other preclinical pipeline includes ZW191 - TOPO1i antibody-drug conjugate for ovarian and gynecological cancers and ZW171 for solid tumors. Zymeworks technology platform comprises Azymetric, Zymelink, Efect and Protect. It operates in the US and Canada. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
Headquarters
United States of America
Address
108 Patriot Drive, Suite A, Middletown, Delaware, 19709
Website
www.zymeworks.com
Telephone
1 302 2748744
No of Employees
272
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZYME (NASD)
Revenue (2022)
$76.0M
-81.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-195.4%
(2022 vs 2021)
Market Cap*
$624.5M
Net Profit Margin (2022)
XYZ
-618.0%
(2022 vs 2021)
* As of and is in US$
Zymeworks Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Zymeworks |
| Zanidatamab (Biliary Tract Cancers, Breast Cancer, Gastroesophageal Adenocarcinomas and Colorectal Cancer) | ProTECT |
| Zanidatamab Zovodotin (HER2-Expressing Cancers) | EFECT |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Zymeworks Inc | Seagen Inc | Puma Biotechnology Inc | MacroGenics Inc | AngioChem Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Canada |
| City | Middletown | Bothell | Los Angeles | Rockville | Westmount |
| State/Province | Delaware | Washington | California | Maryland | Quebec |
| No. of Employees | 272 | 3,256 | 185 | 339 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenneth Galbraith | Chairman; Chief Executive Officer | Executive Board | 2022 | 60 |
| Christopher Astle | Chief Financial Officer; Senior Vice President | Senior Management | 2021 | 43 |
| Neil Klompas | Chief Operating Officer; President | Senior Management | 2017 | 51 |
| Jeffrey Smith | Chief Medical Officer; Executive Vice President | Senior Management | 2024 | - |
| Paul Moore | Chief Scientific Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward